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Abstract: The first part of this paper reviews the current development and key issues on 
implantable multi-sensor devices for in vivo theranostics. Afterwards, the authors propose 
an innovative biomedical multisensory system for in vivo biomarker monitoring that could 
be suitable for customized theranostics applications. At this point, findings suggest that 
cross-cutting Key Enabling Technologies (KETs) could improve the overall performance 
of the system given that the convergence of technologies in nanotechnology, biotechnology, 
micro&nanoelectronics and advanced materials permit the development of new medical 
devices of small dimensions, using biocompatible materials, and embedding reliable  
and targeted biosensors, high speed data communication, and even energy autonomy. 
OPEN ACCESS
Sensors 2014, 14 19276 
 
 
Therefore, this article deals with new research and market challenges of implantable sensor 
devices, from the point of view of the pervasive system, and time-to-market. The remote 
clinical monitoring approach introduced in this paper could be based on an array of 
biosensors to extract information from the patient. A key contribution of the authors is that 
the general architecture introduced in this paper would require minor modifications for the 
final customized bio-implantable medical device.  
Keywords: implantable multi-sensor; biosensor; biotelemetry; biocompatible; KET; 
nanomedicine; personalized medicine; innovation 
 
1. Introduction 
The current interaction between medicine and technology permits the development of new 
diagnostic devices to detect or monitor pathogens, ions, diseases, etc. Doubtless, the integration of 
rapid advances in areas such as microelectronics, microfluidics, microsensors and biocompatible 
materials entails the availability of implantable biodevices for continuous monitoring or event 
detectors that carry out faster and cheaper clinical tasks than when these are done by standard methods. 
Implantable devices have already been used in millions of patients [1]. Benefits of these approaches 
include improved care and quality of life [2]. Implantable sensor networks can facilitate an early 
detection of emergency conditions and diseases in patients at risk, [3] comprising physical, 
physiological, psychological, cognitive, and behavioral processes [4], by reaching inaccessible 
environments in a reduced response time [5]. 
It is in this context that we present a proposal of an integrated front-end architecture for in vivo 
customized detection. A new and challenging scenario defined as the pervasive system is focused on 
the development of systems capable of monitoring human bodily functions and to transmit the 
resultant data for a clinical patient’s monitoring [6]. Thanks to this approach, it could be possible to 
monitor patients anywhere and at all times with important impact on their quality of healthcare 
preventing the worst scenarios for the patients as well as improving the wellbeing and continuing 
activity of the whole population. The possibility of controlling how a therapy is working, detecting 
symptoms, and knowing how the disease is progressing will improve the personalized medical care 
known as theranostics. Patients at risk because of their genetic background, chronically ill or elderly 
people will be monitored outside of and beyond visits to the hospital or at the surgery. Here, the 
significant advantage is to monitor patients in their routine daily activities, as traditional clinical 
monitoring would be replaced by continuous and remote monitoring [7]. This could have a great 
impact on patients’ quality of life and could reduce the cost of the overall healthcare system [8]. 
Across all medical applications and diseases, findings suggest that chronic illness deserves special 
attention [9], particularly in the case of cardiovascular illness [10]. 
With the aim of medically monitoring the patients, there are two different approaches that are 
typically used: external body sensors, and implantable devices, i.e., non-invasive approaches versus the 
invasive ones. In the case of external sensors for non-invasive physiological monitoring [11], a 
multiplatform is suggested [12], with particular interest in the wearable solutions and unobtrusive 
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sensing methods [13,14] and, in particular, the most recent advances in textile-based electronics are 
relevant [15]. In the case of the invasive techniques that are the focus of this document, the type of 
solutions that have been developed, and those which are currently in progress [16], have as a classic 
example the cardiac implant, which was the initial application of these devices, now with advanced 
capabilities such as recently reported by Lee et al. [17]. The evolution of semiconductor technology, 
with low-voltage and low-power electronics, allows the integration of several implantable devices for 
different functions. These approaches could also be combined in order to define a body sensor network 
(BSNs) [18]. The placing of a central control node that acts as a master node, with other slave nodes 
located on or inside the body, monitoring different vital signals, defines a typical wireless network that 
could fulfil the theranostics needs of the patients. 
Theranostics covers a wide range of applications as health interventions with drugs 
(pharmacogenomics), nutrition (nutrigenomics) and vaccines (vaccinomics), as well as diagnostics for 
human diseases [19]. Implantable medical devices are widely used for therapeutic [5] or life-saving 
purposes such as cardiac arrhythmia, diabetes, and Parkinson’s disease [20]. Applications include drug 
delivery systems, pacemakers, implantable cardiac defibrillators (ICDs) and Neurostimulators [1]. 
Some real-time monitoring applications include physiological parameters like blood pressure, glucose 
levels and collecting data for further analysis [5]. 
These devices often contain electronic components that perform increasingly sophisticated sensing, 
computation, and actuation, in many cases without any patient interaction [1] as in the applications 
mentioned above, performing complex analyses with sophisticated decision-making capabilities. They 
are capable of storing detailed personal medical information, and communicate automatically, 
remotely, and wirelessly [2]. Implanted biosensors form a wireless network that can be used for data 
aggregation and data dissemination applications [5].  
The system introduced in this paper is conceived to be implanted under the human skin. The 
powering and communication between this device and an external primary transmitter are based on an 
inductive link [21]. The design presents two different approaches: defining a true/false alarm system 
based on either amperometrics or impedance into a grid of nano-biosensors that could permit the 
monitoring of several diseases by in vivo analysis of the corresponding biomarkers.  
2. Description and Challenges of a Customized Biomedical Implantable Device 
2.1. State-of-the-Art of the Multipurpose Diagnosis Implantable Devices 
Many different problems need to be overcome in obtaining the ideal implantable device [22]. First 
and foremost, the device must be biocompatible to avoid unfavourable reactions within the body. 
Secondly, the medical device must provide long-term stability, selectivity, calibration, miniaturization 
and repetition, as well as power in a downscaled and portable device. In terms of the sensors, label-free 
electrical biosensors are ideal candidates because of their low cost, low power and ease of miniaturization. 
Recent developments in nanobiosensors provide suitable technological solutions in the field of glucose 
monitoring [23,24], pregnancy and DNA testing [25], and microRNA detection [26]. Electrical 
measurement, when the target analyte is captured by the probe, can exploit voltometric, amperometric 
or impedance techniques. Ideally, the device should be able to detect not just one target agent or 
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pathology, but rather several different agents and it should be capable of working in a  
closed-loop feedback, as described by Wang [27] in the case of glucose monitoring. 
Several biomedical devices for in vivo monitoring are currently being developed [24,28,29]. Thus, 
highly stable, accurate intramuscular implantable biosensors for the simultaneous continuous monitoring 
of tissue lactate and glucose have recently been produced, including a complete electrochemical  
cell-on-a-chip. Moreover, with the parallel development of the on-chip potentiostat and signal 
processing, substantial progress has been made towards a wireless implantable glucose/lactate sensing 
biochip [30]. Elsewhere, implantable bio-micro-electromechanical systems (bio-MEMS) for the in situ 
monitoring of blood flow have been designed [31]. Here, the aim was to develop a smart wireless 
sensing unit for non-invasive early stenosis detection in heart bypass grafts. Interestingly, this study 
examines the use of surface coatings in relation to biocompatibility and the non-adhesion of blood 
platelets and other blood constituents. In this case, the nanotechnology as a KET seems to be a useful 
tool for improving the biocompatibility of silicon bio-MEMS structures. 
A theranostic device has one or more specific molecular recognition markers for cells on the surface 
thereof, wherein the recognition markers are selected from the group consisting of peptides, proteins, 
antibodies, antigens, aptamers, molecular imprinted polymers and polynucleotides. When the device is 
implanted in a body, cellular ingrowth is controlled, with desired cell types anchoring and proliferating 
on the implant’s surface to generate a thin layer, and thereafter ceasing accumulation. The cellular 
layer thereby presents a biomimetic surface acceptable to the body, and also presents a low barrier to 
diffusion of analytes with at least substantially constant diffusion characteristics, allowing the use of an 
analyte sensor within the article. 
In biomedical research, there is a great need for multipurpose, reliable, and possibly implantable 
telemetric tools. By using sensor inputs, such devices allow the automated gathering of information on 
physiological parameters without restraining or stressing their subjects. For this purpose, a versatile 
implantable and four-channel telemetry data-acquisition unit was implemented by Wouters et al. [32], 
in a 2-pm n-well CMOS process. The dimensions of this single-chip implementation are 4.7 × 7.1 mm2. 
In the form of an implantable or portable telemetry system, a low-power mixed analog-digital CMOS 
integrated circuit combining several sensor interfaces, the processing and control circuitry, and the 
telemetry unit is intended for monitoring body temperature and physical activity.  
A versatile theranostic system was developed by Young Choi et al. [33] for the early detection, 
targeted therapy, and therapeutic monitoring of colon cancer, by using poly(ethylene glycol)-conjugated 
hyaluronic acid nanoparticles (P-HA-NPs) which can selectively accumulate in tumor tissue. For the 
diagnostic application, a near-infrared fluorescence (NIRF) imaging dye (Cy 5.5) was chemically 
conjugated onto the HA backbone of P-HA-NPs. Arjang Hassibi has worked in the areas of biosensors 
and bioelectronics, biomedical electronics, and integrated circuit design. His company, InSilixa, is 
working on a multi-diagnostic system, using semiconductor-integrated DNA-sequencing technologies 
to create point-of-care diagnostics devices. The idea is to take advantage of “large-volume 
semiconductor technology,” manufacturing systems that are widely available and well established, to 
gain economies of scale [34].  
An RF-powered wireless three-channel implantable bio-sensing microsystem has been developed 
with blood pressure, EKG, and core body temperature sensing capability for untethered genetic tests. A 
flat silicone blood pressure sensing cuff with a MEMS capacitive pressure sensor is employed to form 
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a novel less-invasive blood pressure sensor, which avoids vessel occlusion, bleeding, and blood 
clotting associated with the conventional catheter-based sensors. The implantable microsystem can be 
powered by an adaptively controlled external RF energy source at 4 MHz to ensure a stable on-chip 
power supply. On-going research efforts are devoted to demonstrating in vivo performance in 
laboratory animals [35]. 
Finally, a patent (US 8750961 B1) with a multi-axis, multi-purpose sensor for use with implantable 
medical devices, and for simultaneously detecting the patient’s posture and activity level has been 
developed [36]. The sensor includes a hermetically sealed, fluid-tight, bio-compatible housing. The 
housing is formed of a plurality of adjacently secured sides, and a plurality of side electrodes coupled 
to the sides. A central electrode is disposed at the geometric center of symmetry of the housing, to 
allow measurement of voltage changes between the central electrode and the side electrodes. A  
non-toxic electrically conductive electrolyte fills about half the housing, and immerses part of the 
central electrode and the side electrodes. The sensor further includes a low frequency bandpass filter 
for passing low frequency signals indicative of the patient’s posture, and a high frequency bandpass 
filter for passing high frequency signals indicative of the patient’s activity.  
2.2. Research Challenges in Implantable Devices 
The new generation of implantable devices must overcome some main barriers at its conception 
stage as for example: size, energy available, power dissipation, power management, signal processing, 
communication of the measured data, bio-compatibility, chip-level integration, packaging, bioethics, 
and biosecurity [37]. A conceptual body map of commercial and in development phase implantable sensors 
is depicted in Figure 1, focussed on the most relevant disease processes based on Oesterle et al. [16].  
Figure 1. Mapping of implantable devices (based on [16]). 
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There are very interesting implementations that combine ASICs, MEMS, and the design of 
integrated antennas for the RF powering of the system and the telemetry of the data, based on a link 
between external and internal coils. A fully wireless implantable cardiovascular pressure sensing 
system was developed by Chow et al. [38], combining a 130-nm technology and a MEMS capacitive 
sensor, powering the system through an external 35-dB-m RF powering at 3.7-GHz, with a distance 
range up to 10 cm inside the body, with a telemetry capability of 42.2 kb/s of channel data-rate, 
operating at 2.4-GHz and with a medical stent of 3 cm long. Cleven et al. [39] have also developed 
another interesting application regarding cardiovascular problems, where an implantable wireless 
system for monitoring hypertension is presented. The capacitive sensor, which is based on a MEMS 
implementation in a metal capsule, and the electronics (ASIC), forms a tip of 20 cm that will be placed 
in the femoral artery. In this case, the telemetry and powering is fixed at 133-kHz, with a maximum 
distance of 10 cm. 
In Majerus et al. [40], a bladder-pressure-sensing implantable for chronic patients is introduced, 
based on a specific ASIC design, and also based on a RF powering (LC coupling at 3-MHz), and 
telemetry solution, but operating in an unlicensed ISM band (27.12-MHz), and a rechargeable battery 
solution. In this case, the size is also based on medical constraints given by minimally invasive 
cystoscopic surgery, defining a final capsule of 7-mm wide by 4-mm thick by 15-mm long. Another 
interesting implementation is related to glaucoma [41]. In this case, an RF intraocular pressure monitor 
is implemented based also in a MEMS solution for the sensor and in RF wireless transmission at  
2.4-GHz and RF powering operating at 3.65-GHZ. In this way, RF powering and telemetry path are 
isolated in the same way as in the other examples. An additional approach is presented in  
Pivonka et al. [42], where RF powering and biomedical telemetry at 1.8-GHz are combined with the 
aim of developing a locomotive implantable. 
Other interesting examples for close-loop systems are presented in [17,43,44]. Salam et al. [43] 
developed an implantable drug delivery system for the treatment of refractory epilepsy. The system is 
able to acquire real-time epileptic detection with focal antiepileptic drug injection feedback, combining 
electronics, pumps, reservoirs, etc. Lee et al. [17] presented an implantable microstimulator applied in 
a closed-loop cardiac pacemaker. Monge et al. [44] reported a fully intraocular epiretinal prosthesis, 
based on a 65 nm CMOS ASIC with 512 independent channels, integrated with a flexible MEMS 
origami coils, for the inductive powering at 10-MHz, and telemetry at 160-MHz, and parylene 
substrate to provide the intraocular implant. 
Such complex systems are developed combining different Key Enabling Technologies (KETs) 
which are main contributors to overcoming the challenges involved in the development of an 
implantable device. Figure 2 introduces the suggested share of cross-cutting KETs involved in the 
development of a nano-enabled implantable device for in vivo biomarkers monitoring. 
Current research is focused on the miniaturization and progression of the implants [45], in pursuit of 
less powering and long monitoring devices. The ongoing evolution in this field is based on the higher 
technological capabilities of microelectronic technologies, with higher density of integration, and 
involving a blend of MEMS, packaging and interconnects. The possibility of integrating new dedicated 
miniature transducers, such as pressure sensors [46], for arterial blood oxygen saturation, and 
accelerometers [47] for heart monitoring or cochlear implementations [48] are present examples. The 
progress in miniaturization of lab-on-chip solutions and integrated optics [49] opens the possibility of 
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advances in new implantable medical devices and new challenges, culminating in the theranostic 
approach where the implantable will be able to deliver drugs. The system will implement the right 
algorithms for the control of drug delivery as well as the suitable reservoirs and pumps. This approach 
is feasible with the evolution and progress of MEMS, not particularly from silicon but from flexible 
polymers, and in terms of the lab-on-chip solutions in the field defined by medicine as micromachines [50], 
where there is an active control of fluids. The objective is to deliver drugs in a better way, more 
focalized in the local area or target of interest, rather than through traditional oral medication. The 
system should close the loop, with a monitoring and actuation role. The great paradigm is the artificial 
pancreas, with the design of an implantable system to monitor the glucose level, and a pump injector 
system. The combination of these enabling technologies creates the possibility of moving forward with 
advanced solutions such as artificial organs [50]. 
Figure 2. Suggested distribution of Key Enable Technologies (KETs) in a general 
implantable monitoring device.  
 
In the case of the optic approach, there is a significant limitation of integration, in terms of space, 
and also in terms of its implementation cost, but it is an interesting field of development. This 
approach has some important advantages compared with sensors based on an electrical measurable 
parameter, current or voltage, that make it interesting for integration in future developments. Among 
the benefits are its immunity to electromagnetic radiation, temperature tolerances, fewer risks to 
biological tissues and reliability when working in aqueous solutions. An interesting example is 
presented by Bingger et al. [46], where MEMS and an optoelectronic solution are implemented for 
continuous long-term monitoring of vital medical parameters such as arterial blood oxygen saturation, 
pulse and respiratory frequencies. 
2.2.1. The Powering Module 
A main issue is the way the implant is powered. There are different options, always determined by 
the location of the packaged system, and the available area or volume location for the implantable. The 
first option is to feed the system through a battery [37]. In the field of battery-oriented biomedical and 
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implantable devices [51], the classical approach is based on lithium batteries size C or D, summarized 
in Table 1. 
Table 1. Types of batteries for biomedical devices (based on [51]). 
Cell Size C D R11098 
Diameter (mm) 26.0 33.9 26.92 
Height (mm) 50.5 61.5 42.93 
Thickness (mm) NA NA 8.94 
Weight (g) 65 15.5 28 
Volume (cc) 26.8 55.5 10.33 
Rated Capacity (Ah) 1.9 4.3 0.575 
Current implementations of communication links in implantable devices are not suitable for many 
applications because of their poor harvesting efficiency [52]. Energy harvesting solutions must explore 
if a battery is not an affordable solution: these are defined as self-powered solutions [53]. The first 
solution could be based on electromagnetic induction [54], with various approaches. Some solutions 
propose the implementation of coils on a PCB substrate [55], or coaxial aligned coils with or without a 
ferrite rod [56], with all the attendant problems related to misalignments between the primary 
powering coil and the implanted secondary coil [57] and electronic implementations for a dynamic 
control of the power and voltage generated in the implantable in terms of the actual magnetic field that 
is generated [58]. On the one hand, we have an external element that plays the role of energy wireless 
power source, based on a class E amplifier, powered by the external battery, which supplies power to 
the implantable device through the skin [59,60] (see Figure 3). This powering is local, working for 
instance in the 13.56 MHz ISM (Industrial, Scientific, Medical) band [55], powering 10 mW at a 
distance of 10 mm between coils. The implantable operating at this ISM band must be placed near to 
the external generator. In Kilinc et al. [61], a particular case is presented. A wireless power-transfer  
in vivo implantable device for free moving small animals is derived. The scenario is that the living 
space for the animal is transformed into a full powering base. 
Figure 3. Generic wireless powering of an implantable device. 
 
However, this is one approach for the ISM band. The 13.56 MHz is a very low value. The more 
usual bands, taking into account the need to reduce the size of the implanted antennas and locations to 
place the implants in the body [62], are the bands of 433 MHz, which have similar results to the  
402–405 MHZ MICS (Medical Implant Communication service) band [63], 915 MHZ, 2.45-GHz and 
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5.8-GHz. Currently, there are more works examining the optimization of the design of the implanted 
antennas [64] and the need to analyse the transmission losses between the external antenna and the 
deeply implanted antenna [65]. 
A particular example of this is introduced in Zhang et al. [66]. There, the rectifier module is designed 
to work at the 915-MHz ISM bandwidth (only in region 2). The performance of the RF source is quite 
small, from a typical 4 µW/cm2 for GSM to 1 µW/cm2 for the WiFi band. For coils, typical values are 
lower than 1 µW/cm2, but as much as 1 mW for close inductive coils (a few cm). In the 915-MHz ISM 
bandwidth, at 1.1 m, the energy recovered is around 20 µW [67]. New approaches are being developed. 
In particular, the use of ultrasonic powering instead of RF powering is of great interest. In Zhu et al. [68] 
and Moheimani et al. [69], 1 V is generated with a power capability of 21.4 nW. 
Nevertheless, there are other approaches to power an implantable device without the use of a 
battery. One approach is based on the vibration energy harvesting point of view and the use of  
MEMS [53]. In Abidin et al. [70], a MEMS piezoelectric generator is used to harvest energy from 
vibrations; it also uses supercapacitors as storage elements. An example of a MEMS designed for 
implantable devices is given in Martinez-Quijada and Chowdhury [71], where it is stated that the  
micro-generator is able to generate more energy per unit volume than conventional batteries; that is, an 
RMS power of 390 µW for 1 mm2 of footprint area and a thickness of 500 µm, which is smaller than 
the volume of a typical battery in a pacemaker. Another approach is based on the use of fuel cells. The 
conception of a fuel cell as a biogenerator for implantable devices has emerged, with interesting results 
like in Zebda et al. [72], where a primary glucose fuel cell is derived for an implantable device. In 
some ways, the basic concept is the use of fluids in the body as a fuel source for the fuel cell, which 
would be an inexhaustible energy source. An interesting approach is the use of glucose as a fuel 
source, or the oxygen dissolved in blood [73,74]. Advanced approaches also explore a shift to the use 
of white blood cell capacities in biofuel cells [75]; or approaches such as that in Siu and Chiao [76], 
where the fuel cell is based on the use of a microorganism to convert the chemical energy of glucose 
into electrical energy, in a PDMS structure. 
2.2.2. The Encapsulation of the System 
Bio-compatibility of the final device is a main barrier and challenge for the spread of implantable 
sensors. The encapsulation has to satisfy different properties, especially with regard to its lifetime. For 
instance, it has to be biocompatible and have a low dielectric constant [77], as well as being conformal 
and resistant. 
Implantation of synthetic medical devices generates an immediate and complex material-related 
inflammatory response, such as blood and tissue incompatibility and bio-fouling [78]. Biofouling of 
the sensor membrane is an important cause of sensor dysfunction [79]. Therefore, the design of 
implantable BioMEMS devices must reduce this immune impact, minimize bio-fouling, reduce the 
physical effect of the implant on the surrounding tissues and reduce the degree of cell adhesion 
achieved by the implanted device. To avoid these adverse physiological effects, the implanted devices 
must be packaged with bio-compatible materials. However, bio-compatible materials might not always 
be compatible with the device requirements [78]. 
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Currently, common and widely used materials in implanted biomedical devices with high 
compatibility are polyethylene glycol (PEG), polydimethylsiloxane (PDMS), PTMO (poly tetramethylene 
oxide [78] and parylene-C [80]. Polymer coatings are used for glucose sensors as they reduce the 
diffusion of interferences to the sensor while simultaneously balancing glucose and oxygen diffusion 
to enable an adequate glucose response. They are durable, inert, and capable of tolerating harsh 
environments produced by the FBR. Commonly evaluated polymers are, Nafion, polyurethane, 
polyethylene glycol (PEG), and hydrogels. Nafion is a perfluorosulfonic acid-based polymer that has 
been implemented as a bio-compatible coating. Polyurethane (PU) has been used extensively as an 
outer membrane to act as a bio-compatible interface with the surrounding host tissue. Surface passivation 
with polyethylene glycol (PEG) has been a widely studied strategy for resisting bio-fouling [81]. 
Hydrogels have a modulus similar to subcutaneous tissue and absorb water readily allowing easy 
diffusion of analytes to a sensor. 
In vitro analysis in an osmotic glucose sensor evaluated identified 15 potential candidate materials 
which are shown in Table 2 below [79]. 
Table 2. Candidate materials for implementation in the glucose sensor [79]. 
 Material Abbreviation Specification Manufacturer 
Encapsulation 
Materials 
Sylgard 184 PDMS Polydimethylsiloxane 
Dow Corning Corp., Midland, 
MI 
Araldite 2020 A2020 Epoxy resin Huntsman, Duxford, UK 
Stainless steel Me Corrosion resistant, Type316L
Fosstech Engineering 
Stokke, Norway 
Membrane 
Materials 
Silicon Si 
Silicon with native 2–3 nm 
oxide surface 
HiVe, Horten, Norway 
Silicon Dioxide SiO2 
Silicon with a 500 nm thick 
thermal oxidized surface 
HiVe, Horten, Norway 
Cellulose ester Cm 
Ultrafiltration membrane 
(MWCO 5000 Da, ˜ 2.5 nm 
Spectrum Laboratories Europe 
B.V., Breda, Netherlands 
Polyamide PATF 
Thin Film membrane (MWCO 
0 Da), <1 nm 
Sterlitech Corporation, Kent, 
WA 
Polycarbonate PC 
Track-etched membrane 
(MWCO 500 kDa, ˜ 15 nm) 
Watman, Kent, UK 
Aluminum oxide AAO 
Anodic aluminum oxide 
(MWCO 50 kDa, ˜ 5 nm) 
Synkera Technologies, 
Longmont, CO 
Sensor Carrier 
Materials 
CeramTec GC CT 
Low temperature cofired 
ceramic (LTCC) 
Ceramtec AG, Plochingen, 
Germany 
Dupont 951 DP 
Low temperature cofired 
ceramic (LTCC) 
Dupont, Wilmington, DE 
Sealing Materials 
Silicone 3140 
coating 
S3140 Silicone-based polymer 
Dow Corning Corp., Midland, 
MI 
Silicone 3145 
adhesive 
S3145 Silicone-based polymer 
Dow Corning Corp., Midland, 
MI 
Epo-Tek 353ND ETek Epoxy resin Epoxy Technol., Billerica, MA
Sensors 2014, 14 19285 
 
 
Other biocompatible materials include collagen layer for encapsulation [81], or gold, silicon nitride, 
silicon dioxide and SU-8 for coating use, able to reduce biofouling [82]. Coating of silicon carbide for 
example, can be used to significantly reduce thrombus formation on the surface of the devices, 
especially if the device is exposed to blood [83]. Bouaidat et al. [84] have also mentioned the use of 
phosphorous glass (SiPOC) for cell adhesion in BioMEMS. 
The application of NDGA-crosslinked collagen scaffolds is also a good method for enhancing the 
function and lifetime of implantable bio-sensors by minimizing the in vivo foreign body response.  
Ju et al. [85] have developed a 3D porous and bio-stable collagen scaffold for implantable glucose 
sensors. The scaffolds were fabricated around the sensors and crosslinked using nordihydroguaiaretic 
acid (NDGA) or glutaraldehyde (GA) to enhance physical and biological stability. Kim et al. [86] 
reported an implantable sensor for real-time monitoring of the changes in bladder volume with PDMS 
and parylene-C. They find that both can be used as safe coating materials for the implantable bladder 
volume sensor reported. 
A novel polymer coating consisting of poly(lactic-co-glycolic) acid (PLGA) microsphere dispersed in 
poly(vinyl alcohol) (PVA) hydrogels was evaluated in combination with dummy sensors as a “smart” 
drug eluting bio-compatible coating for implantable biosensors to prevent the foreign body response, 
and thus enhance sensor performance in vivo [80]. Single or multiple electro-spun layers can be used to 
address mass-transport limiting and additional membranes for improving biocompatibility of implantable 
biosensors and other biomedical devices requiring analyte transport, especially the first generation 
implantable glucose biosensors [87]. 
In summary, packaging techniques used must assure a long-term stability and surgical risks must be 
avoided. To fulfil these requirements, available implants in the market typically use hermetic 
packaging in laser-welded enclosures [88]. Nevertheless, for the envisaged miniaturized implants, 
where cans and micro-lids are used, this solution takes too much space. In that case, implantable 
devices for sensing and therapeutic purposes with active regions fully exposed to the physiological 
environment are a great challenge [89]. New approaches based on thin-film coating solutions are in 
progress to overcome these problems [90,91]. In Xie et al. [90] a bilayer solution based on an atomic 
layer deposited (ALD) Al2O3 combined with Parylene C for long-term encapsulation is presented, and 
in Sutanto et al. [91], a packaging and non-hermetic encapsulation MEMS flip chip technology for 
implantable devices is developed. 
2.2.3. The Nano-Biosensor 
Special attention must be focused on nanobiosensors [92]: they need to combine accuracy, 
reliability, precision, life span, manufacturing and scalability, as well as address wealth and 
environmental risks, in order to overcome technological and market bottlenecks. A nanobiosensor or 
nanosensor is generally defined as a nanometre size scale measurement system comprising a probe 
with a sensitive biological recognition element, or bio-receptor, a physicochemical detector component, 
and a transducer in between. Two types of nanosensors with potential medical applications are 
cantilever array sensors and nanotube/nanowire sensors and nanobiosensors, which can be used to test 
nanolitres or less of blood for a wide range of biomarkers.  
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Figure 4. Generic function of several types of biosensor [93]. 
 
Then, a biosensor is a measurement system for the detection of an analyte that combines a 
biological component with a physicochemical detector. The general function of a biosensor is to 
convert binding events between biological receptors and target agents into a signal thanks to a 
transducer which can be based on an optical, a thermal, a gravimetric or an electrochemical detection 
(see Figure 4). This last category has gained increasing attention in the last few years. The high 
sensitivity, low cost and easy miniaturization of the electronic detection taken in conjunction with the 
wide range of applications, has resulted in these devices becoming a perfect analytical tool in different 
fields, such as diagnosis of genetic diseases, detection of infectious agents, study of genetic 
predisposition, development of personalized medicine, detection of differential genetic expression, 
drug screening, etc. 
The development of highly sensitive and low-cost sensors in the nanoscale, and its combination with 
nano-microfluidics solutions [94], based on micro-channels, micromixers and microvalves, are 
increasing the interest in the implementation of multi-parametric point-of-care devices, as a portable and 
low-cost solution to enhance diagnostics methods. In summary, Figure 5 shows principal technologies, 
challenges and materials for multipurpose implantable sensors.1–33,35,36,39–41,43,44,48,95–97].  
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Figure 5. Summary of main devices for biomarkers monitoring. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
3. Conception of the Bio-Implantable Customized Multi-Sensor  
3.1. A Multipurpose Biosensor Architecture 
Instead of defining a particular architecture of the implantable device for each sensor, the new 
approach in this paper introduces the design and use of a general architecture that will require minor 
modifications for a final customized implantable device which could be suitable for a set of  
specific applications.  
The objective is to have a generic array of nanosensors (electrodes) as an implantable system. 
Figure 6 shows the combination of cell clinic solutions concept as a lab-on-a-chip and electrical 
sensing techniques in a single implantable device. 
The envisaged concept is applied in the definition of an on-chip configurable array of biosensors. 
This configuration will take place before the implantation thanks to a standard programmable  
bio-nano-chip approach [34]. A modular standard lab-on-a-chip approach will be followed to adapt the 
sensors in a quick, efficient and reliable way and then the implantable system will be placed into the 
patient (Figure 7). This concept of programmable platform could be adopted with the aim of 
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developing a POC external device. These electrodes will be functionalized before the implantation in 
the human being thanks to the microfluidics (inflow/outflow) circuitry. Afterwards, the sensors will be 
checked and the chip cleaned and ready for the implantation. 
Figure 6. Schematic of the multi-parametric configurable implantable biochip system. 
 
The system will be enabled thanks to a system-on-a-chip (SoC) technology. CMOS 
microelectronics, MEMS and microfluidics will be combined to implement the programmed implantable, 
and easily adapted for the specific needs of the patient. The generic ASIC will combine the integrated 
electronics with an array of nano-biosensors (Sensors array), depicted as electrodes in Figure 6, which 
would be functionalized for particular purposes [98]. Generic modules for the power management, 
narcoleptic system design (NSD), communications, signal processing, the processor and data logging 
will be integrated to fulfil time-to-market constraints. 
Tsai et al. [99] addressed the concept of the envisaged integrated multi-analyte biochip for an 
implantable device, in terms of the fabrication, where microfluidics (PDMS micro-channel), and a 
dielectrophoresis concentrator (DEP) are combined with external discrete electronics. The aim of the 
microfluidic system is to prepare and transport the fluid into the microcapillaries. Then, the preparation 
step consists in the separation of the fluidic and/or suspended particles [100], the mixing of the fluids 
for cell activation and mixing reactants for initiation. It could take place along the capillaries or inside 
of created droplets. These droplets are also useful to encapsulate biological particles or chemical 
reagents. In some cases, the sample also needs to be focalized [101] before it flows through the 
electrical or optical detection system as seen in Figure 7. 
Based on the concept of Tsai et al. [99], the implantable multi-purpose sensor will be defined by the 
combination of configurable sensors as, for instance, glucose sensor [102,103], thermal metabolic 
sensor [104], PH and other sensors to detect the concentration of molecules, typically metabolites, such 
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as glucose, lactose, sodium or ATP as examples of endogenous molecules, or exogenous molecules, 
such as etoposide and ifosfamide.  
Figure 7. Microfluidic configurable array of biosensors on-chip. 
 
3.2. The Electronic Design 
The envisaged integrated electronics is depicted in Figure 8. The ASIC will combine all the 
necessary electronic modules with the sensors’ array of the functionalized biosensors. When the 
implantable is placed in the body, a programmed check of the state of the biosensors should take place. 
The system will check the sensors’ array during the implantable life, and send a critical message to the 
final user if a malfunction is detected and the implantable must be removed while it is implanted. 
Figure 8. Bloc diagram of the proposed implantable architecture. 
 
The system will be based on the use of two different antennae, but it could be based on just one: one 
will be working at a lower frequency to harvest energy (power link), based on the previously presented 
concept of inductive powering, and a second antenna operating at higher frequencies for the 
communications (communications link). In this case, the communication link can be established 
around hundreds of MHz (usually in the 400 MHz ISM band) allowing higher communication rates 
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and reducing the size of the antenna, as previously stated. The first antenna is focused to power the 
electronics through a dedicated inductive link operating at lower frequencies than the communication 
antenna. In that way, each antenna can be optimized for its functionality. 
It is also possible to use just an inductive link for both purposes, and bi-directionally transmit the 
data [57]. However, the amount of transmitted information is limited and the size of the antenna is 
considerably bigger. The communication set-up could be based on a simple backscattering, defining an 
AM modulation, which is the approach taken. In our first ASIC implementation an inductive link for 
both purposes, operating at 13.56 MHz, was implemented. This is a good value for low power 
emission and appropriate to a subcutaneous placement. In our design a planar rectangular coil of  
5.5 mm × 14.5 mm with a thickness of 0.5 mm has been designed, as a proof of concept for the 
antenna. It has seven turns with a conductor width of 0.2 mm. The design presents an inductance of 
400 nH and a series resistance of 340 mΩ. 
An AC/DC integrated rectifier generates an unregulated DC voltage from the electromagnetic 
energy delivered through the inductor link in the Power Management Module. The AC/DC block is 
based on a half-bridge NMOS rectified with a bulk control voltage.  
The system has a power-on-reset module (POR) that activates the electronics when enough energy 
has been recovered through the inductive coupling. A LDO and a low-voltage low-power band gap 
reference circuit generate a DC regulated voltage to drive all the on-chip electronics. A NSD module is 
also implemented to enable the different modules thanks to the POR and the BG. The combination of 
these modules defines the Power Management Module. 
Afterwards, the integrated electronics is introduced to drive the biosensor, make the measurement 
and to generate the data to be transmitted (Sensors Signal Conditioning). Usually, a low-voltage,  
low-power potentiostat circuit or similar instrumentations are used to control each sensor of the array 
(Sensor Control Potentiostat). CMOS electronics will be implemented for each of the sensor’s array 
(Chanel Sensor) [105–107], combining different sensing techniques, such as chronoampetometry (CA) 
and cyclic voltammetry (CV), for sensors’ characterization and calibration tasks, or electro-chemical 
impedance spectroscopy (EIS) generated by the Signal Generation Module, which will have the 
capability to generate DC voltages, a DC sweep or AC signal in order to cover the different techniques. 
In this case, we focus our attention on DC internal voltages which are designed to fix a DC voltage for 
the sensor. Three internal voltages of 0.6 V, −0.6 V, and 0.5 V can be selected. These signals are 
generated from the regulation module, based on the implemented band gap reference circuit. In our 
case, for a three electrode case, a low-voltage low-power CMOS potentiostat amplifier was implemented 
for an amperometric measurement. 
These voltage levels could be applied by the potentiostat amplifier to the three electrode biosensor, 
defined by: (a) the working electrode (W), which serves as a surface on which the electrochemical 
reaction takes place and will be functionalized by the lab-on-a-chip module depicted in Figure 6 and 
Figure 7; (b) the reference electrode (R), which measures the potential at the W electrode; and (c) the 
auxiliary or counter electrode (A/C), which supplies the current required for the electrochemical 
reaction at the W electrode. A single potentiostat amplifier occupies an area of 327 μm × 260 μm, and 
has an average power consumption of 51.2 μW, which is smaller than Paglinawan [108] which has an 
area of 0.16 mm2, and a power dissipation of 600 µW, or Ahmadi and Jullien [109] which has a power 
dissipation greater than 150 µW. Its open-loop gain is 60 dB at low frequencies, and 50 dB1 kHz. 
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The current that is generated in the amperometric sensor, which is proportional to the 
electrochemical reaction that is generated at the working electrode, is measured by a transimpedance 
amplifier (TIA). Its input resistance of the design is 1 GΩ@DC, allowing a current detection up to  
1 nA. The current-to-voltage conversion is defined as VTIA = −IW RTRANS, where IW is the current 
through the working electrode and RTRANS is the externally selected gain resistance. A second gain 
stage based on an inverter configuration follows the TIA and adapts the voltage values for the next 
stage, defining the Sensor Conditioning module.  
The measured signal is forwarded to the Data and Modulation Processing modules. In this case a 
simple absence/presence detector is defined in the Chanel Sensor Module. The detection is based on 
the conception of an event-detector and the True/False detector works as an alarm: when the analyzed 
concentration level exceeds, under or over, a threshold value or the system detects the alarm condition, 
then the modulation process is activated to send the information to the external reader using a 
backscattering method through the inductive link, which can be AC or DC modulation. 
3.3. Results 
A bipolar power scheme able to supply a regulated differential voltage of ±1.2 V and a maximum 
current of ±1.5 mA has been implemented. The Texas Instrument® TRF7960 is used as external reader 
with a maximum emission power of 200 mW at 13.56 MHz. The desired on-chip regulated voltages of  
±1.2 V are obtained for a distance up to 20 mm on air between coupling antennae. This analysis has been 
carried out in terms of the distance (Z-axis), between the external antenna and the coil designed in the 
PCB which defines the full implantable, that is, between the reader and the implantable. However, it is 
also necessary to have an approach to the misalignments between both antennas in the XY plane. Figure 
9 depicts the rectified voltage (Vrec) distribution in function of the XY misalignment for Z distances of 
10, 15, and 20 mm. It can be noticed that the further the antenna is placed from the centre the lower the 
rectified voltage is. A more accurate study with human tissue is beyond the scope of this study. 
Figure 9. Distribution of the Vrec voltage in the XY plane for three different distances: 10, 
15 and 20 mm (Reproduced from [60] with kind permission from Springer Science + 
Bussiness Media B.V). 
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A suitable solution for the detection of threshold values is based on the use of comparators, in terms 
of silicon area and power consumption, to detect one or several threshold values with medical interest. 
In the implemented approach, some comparators capable of detecting three different threshold voltages 
(Vth1, Vth2 and Vth3), generated on-chip, have been implemented. These values are used to define a 
simple AM modulation protocol. 
The signal is always a high level “1” but when a threshold value is achieved then a “0” level is 
generated. This functionality is based on the use of the comparators, monostables flip-flops and a very 
simple digital circuitry. As soon as there is enough voltage, the Power-On-Reset module generates a 
signal that activates the circuitry and the antenna starts to transmit continuously a series of “1”. When 
the first threshold level is achieved, the system transmits one zero (Tth1). If the second is reached, two 
zeros are transmitted (Tth2), and when the third is achieved a series of three zeros are sent (Tth3). A zero 
time slot interval is defined as 250 ms (Tth1 = 250 ms). In this way, the external reader can be quickly 
advised every time the desired substance exceeds the programmed threshold level or levels.  
The instrumentation and the communication protocol were validated using several concentrations of 
K4[Fe(CN)]6 in PBS. In this case, a commercial sensor was used [60]. Several cyclic voltammetries 
(CVs) were carried out in order to verify the performance of the Control and conditioning modules. 
These measurements were compared with those obtained with a commercial potentiostat amplifier, the 
CH 1232A from CHInstruments®. These measurements were also used in order to calibrate the setup, 
and check the obtained values of the measured current peaks for the oxidation peak (around 240 mV), 
and the reduction peak (around 170 mV), for each concentration of K4[Fe(CN)]6 in PBS tested, from  
1–5 mM. Also, this setup was used to validate the measured CV shapes obtained by the commercial 
equipment and the full-custom implementation. After the CV characterization some amperometric tests 
were done for different concentrations of K4[Fe(CN)]6 in PBS: 1 mM, 2 mM, 3 mM, 4 mM and finally 
5 mM. Then, an experiment was carried out where the concentration was changed from 1 to 5 mM in 
time, with a fixed voltage of 500 mV in the sensor. This voltage is defined not at the oxidation peak. 
For this value of voltage applied in the sensor, the current varies from an average current of 3 µA  
(1 mM), to 16 µA (3 mM), up to 28 µA (5 mM). This experience was then carried out to validate the 
detection protocol, for a particular case implemented based on three threshold values. These values 
were programmed to detect the variations in the concentrations, defined by: Vth1, Vth2, Vth3, as is 
depicted in Figure 10, taking into account the current expected for each concentration case and 
defining different windows of comparison. When the first threshold is detected, then a first zero is 
transmitted, with a programmed width of 250 ms. When the second threshold level is reached, then 
two zeros are transmitted, in this case with an amplitude of 500 ms. Finally, in the particular case that a 
threshold Vth3 is defined to detect the highest concentration level, the modulation and data processing 
module will generate the longest transmission of zeros, in this case, three zeros with a total width of 
750 ms. 
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Figure 10. Amperometries measured with the prototype with three current levels 
programmed (Reproduced from [60] with kind permission from Springer Science + 
Bussiness Media B.V). 
 
4. Market Approach and Discussion 
4.1. Innovation and Commercialization Chances in a Multi-KETs Scenario 
In September 2009, the European Commission published its communication “Preparing for our 
future: Developing a common strategy for key enabling technologies in the EU” [110]. This strategy 
identifies the need for the EU to facilitate the industrial deployment of KETs in order to make its 
industries more innovative and globally competitive. KETs are one of the key factors in realizing the 
overall policy objectives of Europe 2020, due to the importance of these technologies for the 
competitiveness and innovation of European enterprises as well as for the development of sustainable 
products and processes [111]. In this context, Horizon 2020, the biggest Framework for Research and 
Innovation, has scheduled over 74 billion € for research funding focused on three fundamental pillars: 
24.598 million € intended for Scientific Excellence, 31.748 million € for Society Challenges  
and 17.938 million € for Industrial Leadership. The last one aims to support SMEs in the industrial 
development and application of KETs, considered crucial accelerators for innovation and 
competitiveness [112].  
KETs have been selected according to economic criteria, capital intensity, technology intensity, and 
their value adding enabling role [113]. The six KETs are: Nanotechnology, Micro and Nano Electronics, 
Photonics, Advanced Materials, Biotechnology Industry and Advanced Manufacturing Systems [114]. 
Among them, Nanotechnology is one of the most promising KETs due to its economic and social growth 
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potential, since it has been considered the greatest impulse to technological and industrial development in 
the 21st century and the resource for the next industrial revolution [115–118].  
The integration of different Key Enabling Technologies (KETs) represents a vital activity in H2020. 
About one third of the budget assigned to KETs will go to supporting innovation projects integrating 
different KETs [119]. Cross-cutting KETs activities will in general include activities closer to market 
and applications. The global market volume in KETS are 646 billion euros and substantial growth 
expected is approx. 8% of EU GDP by 2015 [113]. In the Healthcare domain, short (2017) and 
medium (2020) perspectives of cross cutting KETs are shown in the Figure 11. 
Figure 11. Fields for cross-cutting KETS developments in the Health and Healthcare 
Domain [113].  
 
The European Commission stated that the EU has very good research and development capacities in 
some key enabling technology areas, but it has not been as successful in translating these results into 
commercialized manufactured goods and services [110]. R&D projects implemented in FP6 and FP7 
frameworks have successfully delivered a lot of new nanomedicines but few products onto the market. 
In this context, the Commission states that bridging the so called “Valley of Death” to upscale new 
KET technology based prototypes to commercial manufacturing, often constitutes a weak link in the 
successful use of KETs potential. This is meant to be the “European Industrial Renaissance” by 
covering the whole value chain from Lab-to-Market as the principal aim of H2020 [113].  
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4.2. Market Forecast 
The emerging sector of applied nanotechnology is addressed to biomedicine (nanobiotechnology 
and nanomedicine) which is the area of greatest projection of the future [120]. There are currently 247 
nanomedical products that have been approved or that are in several stages of clinical trials. Industry 
market reports describing companies and their products related to nanomedicine and nanobiotechnology 
have also increased in the last several years [121]. It is expected that the annual global market for 
nano-related goods and services will top $3 trillion in 2020 [122]. Beyond, the medical sensors global 
market is expected to reach 15.5 USD billion in 2019, growing at a Compound Annual Growth rate 
(CAGR) of 6.3% from 2013 to 2019 [123]. Findings suggest that market growth for biosensors and 
biochips is virtually exploding. There are markets for biosensing technologies in the Asia-Pacific 
region, which show Compound Annual Growth Rates of 11% (2008–2018). Growth Rates of 10.7% 
occur in the highly developed market of the United States (US). In fact, this market is projected to 
reach $8.5 billion in US currency within five years, in about 2018 [124]. On the other hand, the global 
market for theranostic nanomaterial was valued at $112 billion in 2012 and is expected to reach $188 
billion by 2017, registering a five-year CAGR of 10.8% for the period 2012–2017 [125]. 
Today, the implantable medical device market is oriented to the increasing elderly population and 
the associated increase in the prevalence of chronic degenerative diseases. However, the use of 
microtechnologies and MEMS in implantable devices is still in its infancy with few technologies 
currently approved for marketing in the US [126]. There is no identifiable market in the private sector 
for personalized and precision medicine yet [127]. The Food and Drug Administration (FDA) 
regulatory process will determine the concrete translation from benchtop research to commercialization of 
implantable nanosensors through clear and reasonable regulations. In this context, the FDA is 
collaborating with the interagency National Nanotechnology Initiative (NNI) to help formulate its 
guidelines with respect to many aspects of nanotechnology in the realms of cosmetics, diagnostics, and 
therapeutics [128].  
4.3. Ethics Concerns 
Designers of implantable medical devices have balanced safety, complexity, power consumption, and 
cost. However, today there are new concerns to take into consideration: security and data privacy [1]. As 
biosensors monitoring involves collection of data about vital body parameters from different parts of 
the body and making decisions based on it, the information is of a personal nature and is required to be 
secure [5]. The reason is to protect patients from acts of theft or malice, especially as medical 
technology becomes increasingly connected with other systems via wireless communications or the 
Internet. Implantable medical devices, including pacemakers, cardiac defibrillators, insulin pumps, and 
neurostimulators feature wireless communication [129].  
Susceptibility to security breaches could compromise performance safety and the privacy of  
patients [2]. Burleson et al. [1] stated that there are two types of vulnerability: privacy, in which 
patient data is exposed to an unauthorized party, and control, in which an unauthorized person gains 
control of the device’s operation or even disables its therapeutic services.  
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There is a need to ensure the privacy and security of medical data [4]. Recent analyses of 
implantable medical devices have revealed several security and privacy vulnerabilities [1]. For 
example, wireless connectivity could compromise the confidentiality of transmitted data or send 
unauthorized commands to the device [129]. Privacy specifications seem to be vague [4], in fact 
medical devices vary widely with regard to security features because no specific security guidance or 
requirements have been promulgated by the FDA [2]. 
Privacy-preserving methods should be developed for the comfort of the people monitored [3] and 
ensure reliable, secure communication and continued functionality while preserving patients’ safety, 
confidentiality, and data integrity. There is nearly universal agreement on the importance of security 
for personal health information and electronic health records, but there is still a disagreement over the 
security requirements for medical devices [2]. 
Security must be considered in early design phases [1]. Some approaches have explored the 
feasibility of protecting an implantable device from privacy attacks by implementing security 
mechanisms entirely on an external device [129] or by encrypting data [1–3]. Moreover, in an effort to 
ensure security, personal authorizations and authentication have been proposed [20]. Therefore, 
Information and Communication Technologies (ICT) systems must facilitate the re-design of the 
current processes of care and follow up through the provision of services that enable the correct 
management of the patients within the healthcare organizations [130].  
New and emerging technologies upset established moral norms by bringing to surface issues which 
were not previously open for discussion [131]. Argumentative patterns in this field are now known as 
NEST-Ethics (New & Emerging Science and Technology Ethics) [132].  
5. Conclusions 
After the revision of the current state-of-the-art of the implantable multi-sensor devices, the authors 
propose a generic multipurpose in vivo implantable biomedical device capable of detecting several 
threshold values for targeted concentrations. As a result, an integrated front-end architecture for in vivo 
customized detection is embedded within an implantable device with a generic array of nanosensors 
combining cell clinic solutions as a lab-on-a-chip and electrical sensing. The key point in this new 
conception is that, instead of defining a particular architecture of the implantable device for each 
sensor, the new approach introduces the design and use of a general architecture that will require  
minor modifications for the final customized implantable device that could be suitable for a set of  
specific applications.  
Given the speed with which chronic diseases are increasing and the aging of the world population, 
the improvements that are possible with new theranostics techniques could have a great impact on the 
wellbeing and quality of life of the whole society while suitable biomedical devices are designed to 
reach a huge market over the next few years. Thus, a successful research, development, innovation and 
technology transfer may be fostered in a particular scenario typified by the convergence of 
technologies and disciplines, as well as by the combination of several KETs allowing the pilot lines 
and commercialization of cutting-edge devices embedding implantable sensors. Amongst all KETs, in 
this blending of technologies, nanotechnology seems to have a great impact, enabling new advantages 
in medical diagnostic or therapeutic devices, from the use of nanomaterials, in the development of 
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nano-biosensors, by using the engineering of surfaces in order to improve the sensitivity of an 
electrode or its biocompatibility, and using nanoparticles from a therapeutic or diagnostic point of 
view, allowing modulation of treatment to particular targets within the human body, and ensuring 
delivery in an optimal way for a specific patient. 
Although the case study reported in this paper is complex because it involves multiple organizations 
and sources of data, it contributes to extending experience to the most recent developments and 
practices on implantable sensors. The next step involves the development of a configurable 
application-specific integrated circuit (ASIC) working with a multiplexed array of nanobiosensors 
designed to be reactive for a set of target agents (enzymes, viruses, molecules, chemical elements, 
molecules, etc.). In this way, multiple sensors of the array can be used for one specific target, while 
other arrays can be prepared for the other targets, while also seeking a redundant response. As a result, 
a customized panel of biomarkers will be ready to be embedded into the bioimplantable medical 
device: each array will be used to detect a specific type of target, and the multiplexed system will be 
used to analyze each array focusing on a particular target. Then, top down approaches using 
nanoengineering and nanofabrication and bottom up approaches using supramolecular chemistry can 
produce novel diagnostics which will increasingly focus on delivering a personalized solution based on 
a real time analysis of array data, and where appropriate, applying this decision to deliver an 
automated therapy (theranostics). 
The modular standard lab-on-a-chip approach introduced in this work may adapt the sensors in a 
quick, efficient and reliable way. Moreover, the system described in this paper must be tested before its 
implementation in a human being, and a POC platform would be designed for this purpose. The  
multi-parametric configurable implantable biochip system would be placed as a plug-and-play device. 
Moreover, it is needed to place a chip in the electronics module for the generation of the CV signals to 
check the sensors after their functionalization. Communications and powering will follow the same 
wireless approach as the implantable device. Once the performance of the sensors has been certified 
and cleaned-up, the implantable system will be suitable for being placed in the patient. This concept of 
programmable platform could be adopted in the design of a POC external device. 
On the other hand, despite the somewhat limited availability of information discussing the safety of 
implantable sensors, the case study presented in this paper is a clear demonstration of how to take into 
account biocompatibility challenges and ethical concerns to foster the development of new 
bioimplantable medical devices. At this point, the bonds between the science community, hospitals, 
industry and citizens need to be strengthened with the aim of enhancing biomedical research on 
implantable sensors and its commercialization. Doubtless, biomedical devices represent a strategic 
gamble for the future of scientific and technological policy areas as they seek accelerated economic 
growth within the knowledge-based society and confront the new scientific and market challenges 
presented by the nano-enabled implantable biomedical devices. 
Finally, the present and future of the implantable devices goes beyond these objectives and research 
challenges. There is a great transformation in medical diagnostics and the blend of the different KETs 
for the integration and commercialization of these devices should follow a standardization process to 
propel them in a Moore’s Law trajectory as happened with the microelectronics revolution. 
Sensors 2014, 14 19298 
 
 
Author Contributions 
Esteve Juanola-Feliu is the corresponding author of this paper and its main contribution is to 
introduce a new conception of personalized implantable sensors that will require minor modifications 
for the final customized implant. Moreover, he promotes to bridge the gap from the lab to the  
market fostering innovation and technology transfer in the fields of nanobiotechnologies and 
biomedical devices.  
Pere Miribel-Català and Jordi Colomer-Farrarons contribute with the state-of-the-art of the 
implantable devices as well as designing an integrated front-end architecture for in vivo customized 
detection and the corresponding electronic modules and measurements.  
Cristina Páez-Avilés contributes with the market research, the multi-KET approach and ethics 
concerns for implantable sensors. 
Manel González-Piñero contributes with the innovation process and value enhancement of the 
biomedical research focused on implantable sensors. 
Josep Samitier is the director of the research group and supports applied research and innovation on 
biomedical engineering.  
Conflicts of Interest 
The authors declare no conflict of interest. 
References  
1. Burleson, W.; Clark, S.S.; Ransford, B.; Fu, K. Design challenges for secure implantable medical 
devices. In Proceedings of the 49th Annual Design Automation Conference on – DAC ’12, San 
Francisco, CA, USA, 3–7 June 2012; pp. 12–17. 
2. Maisel, W.H.; Kohno, T. Improving the security and privacy of implantable medical devices.  
N. Engl. J. Med. 2010, 362, 1164–1166. 
3. Darwish, A.; Hassanien, A. Wearable and implantable wireless sensor network solutions for 
healthcare monitoring. Sensors 2011, 11, 5561–5595. 
4. Ko, J.; Lu, C.; Srivastava, M.; Stankovic, J.; Terzis, A.; Welsh, M. Wireless sensor networks for 
healthcare. Proc. IEEE 2010, 98, 1947–1960. 
5. Cherukuri, S.; Venkatasubramanian, K.K.; Gupta, S.K.S. Biosec: A biometric based approach for 
securing communication in wireless networks of biosensors implanted in the human body. In 
Proceedings of the 2003 International Conference on Parallel Processing Workshops, Kaohsiung, 
Taiwan, 6–9 October 2003; pp. 432–439. 
6. Shen, X.; Misic, J.; Kato, N.; Langenorfer, P.; Lin, X. Emerging technologies and applications of 
wireless communication in healthcare. J. Commun. Netw. 2011, 13, 81–85. 
7. Garcia-Morchon, O.; Falck, T.; Heer, T.; Wehrle, K. Security for Pervasive Medical Sensor 
Networks. In Proceedings of the 6th Annual International Conference on Mobile and Ubiquitous 
Systems: Computing, Networking and Services, Toronto, ON, Canada, 13–16 July 2009;  
pp. 1–10. 
Sensors 2014, 14 19299 
 
 
8. Zweifel, P.; Felder, S.; Meiers, M. Ageing of population and health care expenditure: A red 
herring? Health Econ. 1999, 8, 485–496. 
9. Koutkias, V.G.; Chouvarda, I.; Triantafyllidis, A.; Malousi, A.; Giaglis, G.D.; Maglaveras, N. A 
personalized framework for medication treatment management in chronic care. IEEE Trans. Inf. 
Technol. Biomed. 2010, 14, 464–472. 
10. Zhou, H.; Hou, K. Pervasive Cardiac Monitoring System for Remote Continuous Heart Care. In 
Proceedings of the 2010 4th International Conference on Bioinformatics and Biomedical 
Engineering, Chengdu, China, 18–20 June 2010; pp. 1–4. 
11. Ha, S.; Kim, C.; Chi, Y.M.; Akinin, A.; Maier, C.; Ueno, A.; Cauwenberghs, G. Integrated 
circuits and electrode interfaces for noninvasive physiological monitoring. IEEE Trans. Biomed. 
Eng. 2014, 61, 1522–1537. 
12. ElHelw, M.; Pansiot, J.; McIlwraith, D.; Ali, R.; Lo, B.; Atallah, L. An integrated multi-sensing 
framework for pervasive healthcare monitoring. In Proceedings of the 3rd International ICST 
Conference on Pervasive Computing Technologies for Healthcare, ICST, London, UK, 1–3 April 
2009; pp. 1–7. 
13. Olivo, J.; Brunelli, D.; Benini, L. A kinetic energy harvester with fast start-up for wearable  
body-monitoring sensors. In Proceedings of the 4th International ICST Conference on Pervasive 
Computing Technologies for Healthcare, Munich, Germany, 22–25 March 2010; pp. 1–7. 
14. Zheng, Y.-L.; Ding, X.-R.; Poon, C.C.Y.; Lo, B.P.L.; Zhang, H.; Zhou, X.-L.; Yang, G.-Z.; 
Zhao, N.; Zhang, Y.-T. Unobtrusive sensing and wearable devices for health informatics. IEEE 
Trans. Biomed. Eng. 2014, 61, 1538–1554. 
15. Yoo, H. Your Heart on Your Sleeve: Advances in Textile-Based Electronics Are Weaving 
Computers Right into the Clothes We Wear. IEEE Solid-State Circuits Mag. 2013, 5, 59–70. 
16. Oesterle, S.; Gerrish, P.; Cong, P. New interfaces to the body through implantable-system 
integration. In Proceedings of the 2011 IEEE International Solid-State Circuits Conference,  
San Francisco, CA, USA, 20–24 February 2011; pp. 9–14. 
17. Lee, S.-Y.; Su, Y.-C.; Liang, M.-C.; Hong, J.-H.; Hsieh, C.-H.; Yang, C.-M.; Chen, Y.-Y.;  
Lai, H.-Y.; Lin, J.-W.; Fang, Q. A programmable implantable micro-stimulator SoC with 
wireless telemetry: Application in closed-loop endocardial stimulation for cardiac pacemaker. In 
Proceedings of the 2011 IEEE International Solid-State Circuits Conference, San Francisco, CA, 
USA, 20–24 February 2011; pp. 44–45. 
18. Yang, G.-Z. Body Sensor Networks; Springer-Verlag London: London, UK, 2006. 
19. Pang, T. Theranostics, the 21st century bioeconomy and ‘one health’. Expert Rev. Mol. Diagn. 
2012, 12, 807–809. 
20. Halperin, D.; Heydt-benjamin, T.S.; Maisel, W.H. Security and Privacy for Implantable Medical 
Devices. IEEE Pervasive Comput. 2008, 7, 30–39. 
21. Juanola-Feliu, E.; Colomer-Farrarons, J.; Miribel-Català, P.L.; González-Piñero, M.;  
Samitier, J. Nano-Enabled Implantable Device for In Vivo Glucose Monitoring. In Implantable 
Bioelectronics; Katz, E., Ed.; Wiley-VCH: Weinheim, Germany, 2014; p. 450. 
22. Sadik, O.; Aluoch, A.; Zhou, A. Status of biomolecular recognition using electrochemical 
techniques. Biosens. Bioelectron. 2009, 24, 2749–2765. 
Sensors 2014, 14 19300 
 
 
23. Choi, H.N.; Han, J.H.; Park, J.A.; Lee, J.M.; Lee, W.-Y. Amperometric Glucose Biosensor Based 
on Glucose Oxidase Encapsulated in Carbon Nanotube–Titania–Nafion Composite Film on 
Platinized Glassy Carbon Electrode. Electroanalysis 2007, 19, 1757–1763. 
24. Juanola-Feliu, E.; Colomer-Farrarons, J.; Miribel-Català, P.; Samitier, J.; Valls-Pasola, J. Market 
challenges facing academic research in commercializing nano-enabled implantable devices for in 
vivo biomedical analysis. Technovation 2012, 32, 193–204. 
25. Erdem, A.; Karadeniz, H.; Caliskan, A. Single-Walled Carbon Nanotubes Modified Graphite 
Electrodes for Electrochemical Monitoring of Nucleic Acids and Biomolecular Interactions. 
Electroanalysis 2009, 21, 464–471. 
26. Jamali, A.A.; Pourhassan-Moghaddam, M.; Dolatabadi, J.E.N.; Omidi, Y. Nanomaterials on the 
road to microRNA detection with optical and electrochemical nanobiosensors. TrAC Trends 
Anal. Chem. 2014, 55, 24–42. 
27. Wang, J. In vivo glucose monitoring: Towards “Sense and Act” feedback-loop individualized 
medical systems. Talanta 2008, 75, 636–641. 
28. Wilson, G.; Gifford, R. Biosensors for real-time in vivo measurements. Biosens. Bioelectron. 
2005, 20, 2388–2403. 
29. Valdastri, P.; Susilo, E.; Förster, T.; Strohhöfer, C.; Menciassi, A.; Dario, P. Wireless 
implantable electronic platform for chronic fluorescent-based biosensors. IEEE Trans. Biomed. 
Eng. 2011, 58, 1846–1854. 
30. Rahman, A.; Justin, G.; Guiseppi-Elie, A. Towards an implantable biochip for glucose and 
lactate monitoring using microdisc electrode arrays (MDEAs). Biomed. Microdevices 2009, 11, 
75–82. 
31. Steeves, C.; Young, Y.; Liu, Z. Membrane thickness design of implantable bio-MEMS sensors 
for the in-situ monitoring of blood flow. J. Mater. Sci. Mater. Med. 2007, 18, 25–37. 
32. Wouters, E.; De Cooman, M.; Puers, R. A multi-purpose CMOS sensor interface for  
low-power applications. IEEE J. Solid-State Circuits 1994, 29, 952–956. 
33. Choi, K.Y.; Jeon, E.J.; Yoon, H.Y.; Lee, B.S.; Na, J.H.; Min, K.H.; Kim, S.Y.; Myung, S.-J.; 
Lee, S.; Chen, X.; et al. Theranostic nanoparticles based on PEGylated hyaluronic acid for the 
diagnosis, therapy and monitoring of colon cancer. Biomaterials 2012, 33, 6186–6193. 
34. Chandler, D. Sensing Challenges. IEEE Pulse 2014, 33, 6186–6193. 
35. Young, D.J. An RF-powered wireless multi-channel implantable bio-sensing microsystem. Conf. 
Proc. IEEE Eng. Med. Biol. Soc. 2010, 2010, 6413–6416. 
36. Thompson, D.L. Implantable multi-axis position and activity sensor. U.S. Patent 5233984 A, 1993. 
37. Colomer-Farrarons, J.; Miribel-Catala, P.; Juanola-Feliu, E.; Samitier, J. Ultra-Low-Power 
Harvesting Body-Centred Electronics for Future Health Monitoring Devices Citation 
Information. In Novel Advances in Microsystems Technologies and Their Applications;  
Francis, L., Iniewski, K., Eds.; CRC Press: Boca Raton, FL, USA, 2013; pp. 497–534. 
38. Chow, E.Y.; Chlebowski, A.L.; Chakraborty, S.; Chappell, W.J.; Irazoqui, P.P. Fully wireless 
implantable cardiovascular pressure monitor integrated with a medical stent. IEEE Trans. 
Biomed. Eng. 2010, 57, 1487–1496. 
Sensors 2014, 14 19301 
 
 
39. Cleven, N.J.; Müntjes, J.A.; Fassbender, H.; Urban, U.; Görtz, M.; Vogt, H.; Gräfe, M.; Göttsche, 
T.; Penzkofer, T.; Schmitz-Rode, T.; Mokwa, W. A novel fully implantable wireless sensor 
system for monitoring hypertension patients. IEEE Trans. Biomed. Eng. 2012, 59, 3124–3130. 
40. Majerus, S.J.A.; Fletter, P.C.; Damaser, M.S.; Garverick, S.L. Low-power wireless 
micromanometer system for acute and chronic bladder-pressure monitoring. IEEE Trans. 
Biomed. Eng. 2011, 58, 763–767. 
41. Chow, E.Y.; Chlebowski, A.L.; Irazoqui, P.P. A Miniature-Implantable RF-Wireless Active 
Glaucoma Intraocular Pressure Monitor. IEEE Trans. Biomed. Circuits Syst. 2010, 4, 340–349. 
42. Pivonka, D.; Yakovlev, A.; Poon, A.S.Y.; Meng, T. A mm-Sized Wirelessly Powered and 
Remotely. IEEE Trans. Biomed. Circuits Syst. 2012, 6, 523–532. 
43. Salam, M.T.; Mirzaei, M.; Ly, M.S.; Nguyen, D.K.; Sawan, M. An implantable closedloop 
asynchronous drug delivery system for the treatment of refractory epilepsy. IEEE Trans. Neural 
Syst. Rehabil. Eng. 2012, 20, 432–442. 
44. Monge, M.; Raj, M.; Nazari, M.H.; Chang, H.-C.; Zhao, Y.; Weiland, J.D.; Humayun, M.S.; Tai, 
Y.-C.; Emami, A. A fully intraocular high-density self-calibrating epiretinal prosthesis. IEEE 
Trans. Biomed. Circuits Syst. 2013, 7, 747–760. 
45. Puers, R. Implantable chips and sensors: Quo vadis? In Proceedings of the 2013 IEEE Sensors 
Conference, Baltimore, MD, USA, 3–6 November 2013; pp. 1–2. 
46. Bingger, P.; Fiala, J.; Seifert, A.; Weber, N.; Foerster, K.; Heilmann, C.; Beyersdorf, F.;  
Woias, P.; Zappe, H. In vivo monitoring of blood oxygenation using an implantable MEMS-based 
sensor. In Proceedings of the 2010 IEEE 23rd International Conference Micro Electro 
Mechanical Systems, Wanchai, Hong Kong, 24–28 January 2010; pp. 1031–1034. 
47. Imenes, K.; Andersen, M.H.; Nguyen, A.T.; Tjulkins, F.; Aasmundtveit, K.E.; Hoivik, N.; Hoff, 
L. Implantable MEMS Acceleration Sensor for Heart Monitoring Recent Development and 
Outlook. In Proceedings of the 4th Electronic System-Integration Technology Conference 
(ESTC), Amsterdam, The Netherlands, 17–20 September 2012; pp. 5–9. 
48. Park, W.; O’Connor, K.N.; Mallon, J.R.J.; Maetani, T.; Candler, R.N.; Ayanoor-Vitikkate, V.; 
Roberson, J.B.; Puria, S.; Kenny, T.W. Sub-mm encapsulated accelerometers: A fully 
Implantable Sensor for Cochlear Implants. In Proceedings of the 13th International Conference 
on Solid-state Sensors, Actuators and Microsystems, Seul, Korea, 5–9 June 2005; pp. 109–112. 
49. Albert, J. A lab on fiber. IEEE Spectr. 2014, 51, 48–53. 
50. Borenstein, J. Medicine by micromachine. IEEE Spectr. 2009, 46, 36–41. 
51. Spillman, D.M.; Takeuchi, E.S. Lithium ion batteries for medical devices. In Proceedings of the 
Fourteenth Annual Battery Conference on Applications and Advances, Long Beach, CA, USA, 
12–15 January 1999; pp. 203–208. 
52. Poon, A.S.Y. Miniaturized Biomedical Implantable Devices. In Implantable Bioelectronics; 
Katz, E., Ed.; Wiley-VCH: Weinheim, Germany, 2014; p. 450. 
53. Wang, Z.L. Top emerging technologies for self-powered nanosystems: Nanogenerators and 
nanopiezotronics. In Proceedings of the 3rd International Nanoelectronics Conference (INEC), 
Hong Kong, China, 3–8 January 2010; pp. 63–64. 
54. Raju, S.; Wu, R.; Chan, M.; Yue, C.P. Modeling of Mutual Coupling Between Planar Inductors 
in Wireless Power Applications. IEEE Trans. Power Electron. 2014, 29, 481–490. 
Sensors 2014, 14 19302 
 
 
55. Xue, R.; Cheng, K.; Je, M. High-Efficiency Wireless Power Transfer for Biomedical Implants by 
Optimal. IEEE Trans. Circuits Syst. 2013, 60, 867–874. 
56. Theilmann, P.T.; Asbeck, P.M. An analytical model for inductively coupled implantable 
biomedical devices with ferrite rods. IEEE Trans. Biomed. Circuits Syst. 2009, 3, 43–52. 
57. Lenaerts, B.; Puers, R. Omnidirectional Inductive Powering for Biomedical Implants. Analog 
Circuits and Signal Processing; Springer: Berlin/Heidelberg, Germany, 2009; pp. 1–240. 
58. Zou, L.; Larsen, T. Dynamic power control circuit for implantable biomedical devices. IET 
Circuits Devices Syst. 2011, 5, 297–302. 
59. Ziaie, B.; Nardin, M.D.; Coghlan, A.R.; Najafi, K. A single-channel implantable microstimulator 
for functional neuromuscular stimulation. IEEE Trans. Biomed. Eng. 1997, 44, 909–920. 
60. Colomer-Farrarons, J.; Miribel-Català, P.L. A CMOS Self-Powered Front-End Architecture for 
Subcutaneous Event-Detector Devices: Three-Electrodes Amperometric Biosensor Approach; 
Springer: Berlin/Heidelberg, Germany, 2011; p. 176. 
61. Kilinc, E.; Conus, G.; Weber, C.; Kawkabani, B.; Maloberti, F.; Dehollain, C. A System for 
Wireless Power Transfer in Freely Moving Animals. IEEE Sens. 2014, 14, 522–531. 
62. Kiourti, A.; Nikita, K.S. Miniature Scalp-Implantable Antennas for Telemetry in the MICS and 
ISM Bands: Design, Safety Considerations and Link Budget Analysis. IEEE Trans. Antennas 
Propag. 2012, 60, 3568–3575. 
63. Yang, C.; Tsai, C.; Cheng, K.; Chen, S. Low-Invasive Implantable Devices of Low-Power 
Consumption Using High-Efficiency Antennas for Cloud Health Care. IEEE J. Emerg. Sel. Top. 
Circuits Syst. 2012, 2, 14–23. 
64. Kiourti, A.; Nikita, K.S. Accelerated Design of Optimized Implantable Antennas for Medical 
Telemetry. IEEE Antennas Wirel. Propag. Lett. 2013, 11, 1655–1658. 
65. Murphy, O.H.; McLeod, C.N.; Navaratnarajah, M.; Yacoub, M.; Toumazou, C. A  
Pseudo-Normal-Mode Helical Antenna for Use with Deeply Implanted Wireless Sensors. IEEE 
Trans. Antennas Propag. 2012, 60, 1135–1139. 
66. Zhang, X.; Jiang, H.; Zhang, L.; Zhang, C.; Wang, Z.; Chen, X. An Energy-Efficient ASIC for 
Wireless Body Sensor Networks in Medical Applications. IEEE Trans. Biomed. Circuits Syst. 
2010, 4, 11–18. 
67. Yeatman, E.M. Energy scavenging for wireless sensor nodes. In Proceedings of the 2nd 
International Workshop on Advances in Sensors and Interface, Bari, Italy, 26–27 June 2007;  
pp. 1–4. 
68. Zhu, Y.; Moheimani, S.O.R.; Yuce, M.R. Ultrasonic Energy Transmission and Conversion Using 
a 2-D MEMS Resonator. IEEE Electron Device Lett. 2010, 31, 374–376. 
69. Moheimani, S.O.R.; Yuce, M.R. A 2-DOF MEMS Ultrasonic Energy Harvester. IEEE Sens. J. 
2011, 11, 155–161. 
70. Abidin, H.E.Z.; Hamzah, A.A.; Majlis, B.Y. Design of interdigital structured supercapacitor for 
powering biomedical devices. In Proceedings of the 2011 IEEE Regional Symposium on Micro 
and Nano Electronics, Kota Kinabalu, Malasya, 28–30 Septeber 2011; pp. 88–91. 
71. Martinez-Quijada, J.; Chowdhury, S. Body-Motion Driven MEMS Generator for Implantable 
Biomedical Devices. In Proceedings of the 2007 Canadian Conference on Electrical and 
Computer Engineering, Vancouver, BC, USA, 22–26 April 2007; pp. 164–167. 
Sensors 2014, 14 19303 
 
 
72. Zebda, A.; Cosnier, S.; Alcaraz, J.-P.; Holzinger, M.; Le Goff, A.; Gondran, C.; Boucher, F.; 
Giroud, F.; Gorgy, K.; Lamraoui, H.; Cinquin, P. Single glucose biofuel cells implanted in rats 
power electronic devices. Sci. Rep. 2013, doi:10.1038/srep01516. 
73. Ravariu, C.; Ionescu-Tirgoviste, C.; Ravariu, F. Glucose biofuels properties in the bloodstream, 
in conjunction with the beta cell electro-physiology. In Proceedings of the 2009 International 
Conference on Clean Electrical Power, Capri, Italy, 9–11 June 2009; pp. 124–127. 
74. Von Stetten, F.; Kerzenmacher, S.; Lorenz, A.; Chokkalingam, V.; Miyakawa, N.;  
Zengerle, R.; Ducrée, J. A one-compartment, direct glucose fuel cell for powering long-term 
medical implants. In Proceedings of the 19th International Comference on Micro Electro 
Mechanical Systems, Istanbul, Turkey, 22–26 January 2006; pp. 934–937. 
75. Justin, G.A.; Sclabassi, R. An investigation of the ability of white blood cells to generate 
electricity in biofuel cells. In Proceedings of the IEEE 31st Annual Northeast Bioengineering 
Conference, Hoboken, NJ, USA, 2–3 April 2005; pp. 277–278. 
76. Siu, C.-P.; Chiao, M. A Microfabricated PDMS Microbial Fuel Cell. J. Microelectromech. Syst. 
2008, 17, 1329–1341. 
77. De Vos, P.; Bucko, M.; Gemeiner, P.; Navrátil, M.; Svitel, J.; Faas, M.; Strand, B.L.;  
Skjak-Braek, G.; Morch, Y.A.; Vikartovská, A.; et al. Multiscale requirements for 
bioencapsulation in medicine and biotechnology. Biomaterials 2009, 30, 2559–2570. 
78. Tng, D.; Hu, R.; Song, P.; Roy, I.; Yong, K.-T. Approaches and Challenges of Engineering 
Implantable Microelectromechanical Systems (MEMS) Drug Delivery Systems for in Vitro and 
in Vivo Applications. Micromachines 2012, 3, 615–631. 
79. Sokolov, A.; Hellerud, B.C.; Johannessen, E.A.; Mollnes, T.E. Inflammatory response induced 
by candidate biomaterials of an implantable microfabricated sensor. J. Biomed. Mater. Res. A 
2012, 100, 1142–1150. 
80. Wang, Y.; Papadimitrakopoulos, F.; Burgess, D.J. Polymeric “smart” coatings to prevent foreign 
body response to implantable biosensors. J. Control Release 2013, 169, 341–347. 
81. Nichols, S.P.; Koh, A.; Storm, W.L.; Shin, J.H.; Schoenfisch, M.H. Biocompatible materials for 
continuous glucose monitoring devices. Chem. Rev. 2013, 113, 2528–2549. 
82. Voskerician, G.; Shive, M.S.; Shawgo, R.S.; von Recum, H.; Anderson, J.M.; Cima, M.J.; 
Langer, R. Biocompatibility and biofouling of MEMS drug delivery devices. Biomaterials 2003, 
24, 1959–1967. 
83. Schmehl, J.M.; Harder, C.; Wendel, H.P.; Claussen, C.D.; Tepe, G. Silicon carbide coating of 
nitinol stents to increase antithrombogenic properties and reduce nickel release. Cardiovasc. 
Revasc. Med. 2008, 9, 255–262. 
84. Bouaidat, S.; Winther-Jensen, B.; Christensen, S.F.; Jonsmann, J. Plasma-polymerized coatings 
for bio-MEMS applications. Sens. Actuators A Phys. 2004, 110, 390–394. 
85. Ju, Y.M.; Yu, B.; West, L.; Moussy, Y.; Moussy, F. A novel porous collagen scaffold around an 
implantable biosensor for improving biocompatibility. II. Long-term in vitro/in vivo sensitivity 
characteristics of sensors with NDGA- or GA-crosslinked collagen scaffolds. J. Biomed. Mater. 
Res. A 2010, 92, 650–658. 
Sensors 2014, 14 19304 
 
 
86. Kim, S.-J.; Lee, D.-S.; Kim, I.-G.; Sohn, D.-W.; Park, J.-Y.; Choi, B.-K.; Kim, S.-W. Evaluation 
of the biocompatibility of a coating material for an implantable bladder volume sensor. 
Kaohsiung J. Med. Sci. 2012, 28, 123–129. 
87. Wang, N.; Burugapalli, K.; Song, W.; Halls, J.; Moussy, F.; Ray, A.; Zheng, Y. Electrospun 
fibro-porous polyurethane coatings for implantable glucose biosensors. Biomaterials 2013, 34, 
888–901. 
88. Dawes, C. Laser Welding: A Practical Guide; Woodhead Publishing: Cambridge, UK, 1992;  
pp. 1–258. 
89. Kotzar, G.; Freas, M.; Abel, P.; Fleischman, A.; Roy, S.; Zorman, C.; Moran, J.M.; Melzak, J. 
Evaluation of MEMS materials of construction for implantable medical devices. Biomaterials 
2002, 23, 2737–2750. 
90. Xie, X.; Rieth, L.; Caldwell, R.; Diwekar, M.; Tathireddy, P.; Sharma, R.; Solzbacher, F.  
Long-term bilayer encapsulation performance of atomic layer deposited Al2O3 and Parylene C 
for biomedical implantable devices. IEEE Trans. Biomed. Eng. 2013, 60, 2943–2951. 
91. Sutanto, J.; Anand, S.; Sridharan, A.; Korb, R.; Zhou, L.; Baker, M.S.; Okandan, M.; 
Muthuswamy, J. Packaging and Non-Hermetic Encapsulation Technology for Flip Chip on 
Implantable MEMS Devices. J. Microelectromech. Syst. 2012, 21, 882–896. 
92. Preethichandra, D.M.G.; Ekanayake, E.M.I.M.; Kaneto, K. Development of low-cost  
nano-biosensors to enhance the rural healthcare services. In Proceedings of the 2012 Sixth 
International Conference on Sensing Technology (ICST), Kolkata, India, 18–21 December 2012; 
pp. 163–166. 
93. Colomer-Farrarons, J.; Miribel-Catala, P.; Rodriguez-Villarreal, I.; Samitier, J. Portable  
Bio-Devices: Design of Electrochemical Instruments from Miniaturized to Implantable Devices. 
In New Perspectives in Biosensors Technology and Applications; Serra, P.A., Ed.; InTech: 
Rijeka, Croatia, 2011; p. 374. 
94. Adam, T.; Hashim, U.; Bari, M. Microstructure and polymer choice in microfluidic interfacing 
for nanoscale biosensing. In Proceedings of the 2012 International Conference on Biomedical 
Engineering (ICoBE), Penang, Malaysia, 27–28 February 2012; pp. 227–232. 
95. Son, D.; Lee, J.; Qiao, S.; Ghaffari, R.; Kim, J.; Lee, J.E.; Song, C.; Kim, S.J.; Lee, D.J.;  
Jun, S.W.; et al. Multifunctional wearable devices for diagnosis and therapy of movement 
disorders. Nat. Nanotechnol. 2014, 9, 397–404. 
96. Pang, C.; Lee, C.; Suh, K.-Y. Recent advances in flexible sensors for wearable and implantable 
devices. J. Appl. Polym. Sci. 2013, 130, 1429–1441. 
97. Kim, D.-H.; Lu, N.; Ma, R.; Kim, Y.-S.; Kim, R.-H.; Wang, S.; Wu, J.; Won, S.M.; Tao, H.; 
Islam, A.; et al. Epidermal electronics. Science 2011, 333, 838–843. 
98. Polsky, R.; Harper, J.C.; Wheeler, D.; Brozik, S.M. Multifunctional Electrode Arrays: Towards a 
Universal Detection Platform. Electroanalysis 2008, 20, 671–679. 
99. Tsai, Y.-C.; Chiu, N.-F.; Liu, P.-C.; Ou, Y.-C.; Liao, H.-H.; Yang, Y.-J.; Yang, L.-J.; Lei, U.; 
Chao, F.-S.; Lu, S.-S.; et al. Fabrication Process of Integrated Multi-Analyte Biochip System for 
Implantable Application. In Proceedings of the 2009 IEEE 22nd International Conference on 
Micro Electro Mechanical Systems, Sorrento, Italy, 25–29 January 2009; pp. 204–207. 
Sensors 2014, 14 19305 
 
 
100. Rodríguez-Villarreal, A.I.; Arundell, M.; Carmona, M.; Samitier, J. High flow rate microfluidic 
device for blood plasma separation using a range of temperatures. Lab Chip 2010, 10, 211–219. 
101. Rodriguez-Trujillo, R.; Castillo-Fernandez, O.; Garrido, M.; Arundell, M.; Valencia, A.; Gomila, 
G. High-speed particle detection in a micro-Coulter counter with two-dimensional adjustable 
aperture. Biosens. Bioelectron. 2008, 24, 290–296. 
102. Mitsubayashi, K.; Iguchi, S.; Endo, T.; Tanimoto, S.; Murotomi, D. Flexible glucose sensor with 
a film-type oxygen electrode by microfabrication techniques. In Proceedings of the 12th 
International Conference on TRANSDUCERS, Solid-State Sensors, Actuators and 
Microsystems, Boston, MA, USA, 8–12 June 2003; Volume 2, pp. 1201–1204. 
103. Kudo, H.; Sawada, T.; Kazawa, E.; Yoshida, H.; Iwasaki, Y.; Mitsubayashi, K. A flexible and 
wearable glucose sensor based on functional polymers with soft-MEMS techniques. Biosens. 
Bioelectron. 2006, 22, 558–562. 
104. Sipe, D.M. A MEMS Thermal Biosensor for Metabolic Monitoring Applications.  
J. Microelectromech. Syst. 2008, 17, 318–327. 
105. Gozzini, F.; Ferrari, G.; Sampietro, M. An instrument-on-chip for impedance measurements on 
nanobiosensors with attoFarad resoution. In Proceedings of the 2009 IEEE International  
Solid-State Circuits Conference, San Francisco, CA, USA, 8–12 February 2009; pp. 346–347. 
106. Levine, P.M.; Gong, P.; Levicky, R.; Shepard, K.L. Real-time, multiplexed electrochemical 
DNA detection using an active complementary metal-oxide-semiconductor biosensor array with 
integrated sensor electronics. Biosens. Bioelectron. 2009, 24, 1995–2001. 
107. Ghoreishizadeh, S.S.; Carrara, S.; De Micheli, G. A configurable IC to contol, readout, and 
calibrate an array of biosensors. In Proceedings of the 2013 European Conference on Circuit 
Theory and Design (ECCTD), Dresden, Germany, 8–12 September 2013; pp. 1–4. 
108. Paglinawan, A.C. A 600 μW readout circuit with potentiostat for amperometric chemical sensors 
and glucose meter applications. In Proceedings of the 2007 IEEE Conference on Electron Devices 
and Solid-State Circuits, Tainan, Taiwan, 20–22 December 2007; pp. 1087–1090. 
109. Ahmadi, M.M.; Jullien, G.A. A very low power CMOS potentiostat for bioimplantable 
applications. In Proceedings of the Fifth International Workshop on System-on-Chip for  
Real-Time Applications (IWSOC’05), Alberta, Canada, 20–24 July 2005; pp. 184–189. 
110. European Commission. Cross-sectoral Analysis of the Impact of International Industrial Policy 
on Key Enabling Technologies; European Commission: Copenhagen, Denmark, 2011; pp. 1–216. 
111. European Commission. Preparing for Our Future: Developing a Common Strategy for Key 
Enabling Technologies in the EU; European Commission: Brussels, Belgium, 2009; pp. 1–25. 
112. European Commission. Regional Innovation Scoreboard 2012 Report; European Commission: 
Brussels, Belgium, 2012; pp. 1–74. 
113. European Commission. Key Enabling technologies and Cross-cutting Key Enabling 
Technologies Plenary Session. In Proceedings of the RO-cKETs - multiKETs Pilot Lines 
Conference; Brussels, Belgium, 2–3 April 2014. 
114. ECSIP Consortium. Study on the International Market Distortion in the Area of KETs: A Case 
Analysis; ECSIP Consortium: Copenhagen, Denmark, 2013; pp. 1–112. 
115. Rothaermel, F.T.; Thursby, M. The Nanotech vs. the biotech revolution: Sources of productivity 
in incumbent firm research. Res. Policy 2007, 36, 832–849. 
Sensors 2014, 14 19306 
 
 
116. RNCOS. Nanotechnology Market Outlook 2017; RNCOS: Noida, India, 2013; pp. 1–210. 
117. European Commission. Successful European Nanotechnology Research: Outstanding Science 
and Technology to Match the Needs of Future Society; European Commission: Brussels, 
Belgium, 2011; pp. 1–116. 
118. Flynn, T.; Wei, C. The pathway to commercialization for nanomedicine. Nanomedicine 2005, 1, 
47–51. 
119. European Commission Cross-cutting KETs activities. Available online: http://ec.europa.eu/ 
enterprise/sectors/ict/key_technologies/ro-ckets/index_en.htm (accessed on 9 May 2014). 
120. Miyazaki, K.; Islam, N. An empirical analysis of nanotechnology research domains. 
Technovation 2010, 30, 229–237. 
121. Etheridge, M.L.; Campbell, S.A.; Erdman, A.G.; Haynes, C.L.; Wolf, S.M.; McCullough, J. The 
big picture on nanomedicine: The state of investigational and approved nanomedicine products. 
Nanomedicine 2013, 9, 1–14. 
122. Roco, M.; Mirkin, C.; Hersam, M. Nanotechnology research directions for societal needs in 
2020: Summary of international study. J. Nanoparticle Res. 2011, doi:10.1007/s11051-011-0275-5. 
123. Press Releases Services. Available online: http://www.prweb.com/releases/2014/01/ 
prweb11491906.htm (accessed on 13 May 2014). 
124. Broderick, P.A. Biochips & Tissue Chips Biosensors and Biochips Sense Central and Peripheral 
Disease. J. Biochip Tissue Chip 2013, 3, 1–2. 
125. Press Releases Services. Available online: http://www.prweb.com/releases/2013/8/ 
prweb10988156.htm (accessed on 13 May 2014). 
126. Meng, E.; Sheybani, R. Insight: Implantable Medical Devices. Lab Chip 2014, 14, 3233–3240. 
127. Kim, T.; Lee, S.; Chen, X. Nanotheranostics for personalized medicine. Expert Rev. Mol. Diagn. 
2013, 13, 257–269. 
128. Ruckh, T.; Clark, H. Implantable Nanosensors: Toward Continuous Physiologic Monitoring. 
Anal. Chem. 2013, 86, 1314–1323. 
129. Gollakota, S.; Ransford, B.; Katabi, D.; Fu, K. They Can Hear Your Heartbeats: Non-Invasive 
Security for Implantable Medical Devices. ACM SIGCOMM Comput. Commun. Rev. 2011, 41, 
2–13. 
130. Guillén, A.; Colas, J.; Gutierrez, G. Risk assessment and patient stratification using implantable 
medical devices. The funding for personal health programs. In Proceedings of the 2011 Annual 
International Conference of the IEEE Engineering in Medicine and Biology Society, EMBC, 
Boston, MA, USA, 30 August–3 September 2011; pp. 884–887. 
131. Niculescu-Dinca, V. NEST-ethics in Convergence : Testing NEST-ethics in the Debate on 
Converging Technologies for Improving Human Performance; University of Twente: Enschede, 
Netherlands, 2009; pp. 1–61. 
132. Swierstra, T.; Rip, A. Nano-ethics as NEST-ethics: Patterns of Moral Argumentation about New 
and Emerging Science and Technology. Nanoethics 2007, 1, 3–20.  
© 2014 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/4.0/). 
